PET/CT for Target Delineation of Lung Cancer Before Radiation Therapy.


Journal

Seminars in nuclear medicine
ISSN: 1558-4623
Titre abrégé: Semin Nucl Med
Pays: United States
ID NLM: 1264464

Informations de publication

Date de publication:
11 2022
Historique:
received: 05 05 2022
revised: 11 05 2022
accepted: 12 05 2022
pubmed: 6 7 2022
medline: 26 10 2022
entrez: 5 7 2022
Statut: ppublish

Résumé

In clinical routine of patients suffering from lung cancer, radiotherapy/radiation oncology represents one of the therapeutic hallmarks in the multimodal treatment besides or in combination with other local treatments such as surgery, but also systemic treatments such as chemotherapy, tyrosine kinase, and immune check-point inhibitors. Conventional morphological imagings such as CT or MR are commonly used for staging, response assessment, but also for radiotherapy planning. However, advanced imaging techniques such as PET do continuously get increasing access to clinical routine overcoming limitations of standard imaging techniques by visualizing and quantifying molecular processes such as glucose metabolism, which is also of relevance for radiotherapy planning. This review article summarizes the current place of radiotherapy within the treatment regimens of patients with lung cancer and elucidates current concepts of standard morphological imaging for staging and radiotherapy planning. Moreover, the place of PET-based radiotherapy planning in a clinical context is presented and current methodological/technical advances that do comprise a potential role for radiotherapy planning in lung cancer patients are discussed.

Identifiants

pubmed: 35781392
pii: S0001-2998(22)00053-8
doi: 10.1053/j.semnuclmed.2022.05.003
pii:
doi:

Substances chimiques

Protein-Tyrosine Kinases EC 2.7.10.1
Glucose IY9XDZ35W2

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

673-680

Informations de copyright

Copyright © 2022 Elsevier Inc. All rights reserved.

Auteurs

Farkhad Manapov (F)

Department of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany.

Chukwuka Eze (C)

Department of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany.

Adrien Holzgreve (A)

Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany.

Lukas Käsmann (L)

Department of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany.

Alexander Nieto (A)

Department of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany.

Julian Taugner (J)

Department of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany.

Marcus Unterrainer (M)

Department of Radiology, University Hospital, LMU Munich, Munich, Germany. Electronic address: Marcus.unterrainer@med.uni-muenchen.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH